Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Bone Joint J ; 99-B(11): 1537-1544, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29092996

RESUMEN

AIMS: Calcium sulphate (CaSO4) is a resorbable material that can be used simultaneously as filler of a dead space and as a carrier for the local application of antibiotics. Our aim was to describe the systemic exposure and the wound fluid concentrations of vancomycin in patients treated with vancomycin-loaded CaSO4 as an adjunct to the routine therapy of bone and joint infections. PATIENTS AND METHODS: A total of 680 post-operative blood and 233 wound fluid samples were available for analysis from 94 implantations performed in 87 patients for various infective indications. Up to 6 g of vancomycin were used. Non-compartmental pharmacokinetic analysis was performed on the data from 37 patients treated for an infection of the hip. RESULTS: The overall systemic exposure remained within a safe range, even in patients with post-operative renal failure, none requiring removal of the pellets. Local concentrations were approximately ten times higher than with polymethylmethacrylate (PMMA) as a carrier, but remained below reported cell toxicity thresholds. Decreasing concentrations in wound fluid were observed over several weeks, but remained above the common minimum inhibitory concentrations for Staphylococcus up to three months post-operatively. CONCLUSION: This study provides the first pharmacokinetic description of the local application of vancomycin with CaSO4 as a carrier, documenting slow release, systemic safety and a release profile far more interesting than from PMMA. In particular, considering in vitro data, concentrations of vancomycin active against staphylococcal biofilm were seen for several weeks. Cite this article: Bone Joint J 2017;99-B:1537-44.


Asunto(s)
Antibacterianos/farmacocinética , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Osteomielitis/tratamiento farmacológico , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Infecciones de los Tejidos Blandos/tratamiento farmacológico , Vancomicina/farmacocinética , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/metabolismo , Antibacterianos/uso terapéutico , Sulfato de Calcio , Portadores de Fármacos , Femenino , Infecciones por Bacterias Gramnegativas/metabolismo , Infecciones por Bacterias Grampositivas/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Procedimientos Ortopédicos/instrumentación , Osteomielitis/metabolismo , Estudios Prospectivos , Infecciones Relacionadas con Prótesis/metabolismo , Infecciones de los Tejidos Blandos/metabolismo , Vancomicina/metabolismo , Vancomicina/uso terapéutico
2.
J Environ Qual ; 41(2): 544-53, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22370417

RESUMEN

Modeling is a common practice to evaluate factors affecting water quality in environmental systems impaired by point and nonpoint losses of N and P. Nevertheless, in situations with inadequate information, such as ungauged basins, a balance between model complexity and data availability is necessary. In this paper, we applied a simplified analytical model to an artificially drained floodplain in central-western Italy to evaluate the importance of different nutrient sources and in-stream retention processes and to identify critical source areas. We first considered only a set of chemical concentrations in water measured from February through May 2008 and from November 2008 through February 2009. We then broadened available data to include water discharge and hydraulic-head measurements to construct a hydrogeological model using MODFLOW-2000 and to evaluate the reliability of the simplified method. The simplified model provided acceptable estimates of discharge (ranging from 0.03-0.75 m s) and diffuse nutrient inputs from water table discharge and in-stream retention phenomena. Estimates of PO-P and total P retention (ranging from 1.0 to 0.6 µg m s and from 1.18 to 0.95 µg m s for PO-P and total P, respectively) were consistent with the range of variability in literature data. In contrast, the higher temporal variability of nitrate concentrations decreased model accuracy, suggesting the need for more intensive monitoring. The model also separated the dynamics of different reaches of the drainage network and identified zones considered critical source areas and buffer zones where pollutant transport is reduced.


Asunto(s)
Lagos/química , Modelos Teóricos , Nitrógeno/análisis , Fósforo/análisis , Contaminantes Químicos del Agua/análisis , Agua/química , Difusión , Italia , Nitratos/análisis , Nitratos/química , Nitrógeno/química , Fósforo/química , Contaminantes Químicos del Agua/química
3.
J Endocrinol Invest ; 20(3): 144-50, 1997 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-9186821

RESUMEN

The individual role played by GH and IGF-I in the regulation of hypothalamic GHRH and SRIF gene expression is still object of debate. We have investigated the effect of exogenously administered recombinant hGH (rhGH) and recombinant hIGF-I (rhIGF-I) in ad libitum fed control and starved rats, the latter an animal model which is characterized by low circulating levels of endogenous GH and IGF-I. Adult male rats were fed ad libitum (C) or food-deprived (S) for 72 hours; rats in either C or S groups were treated with systemic administration of rhGH and rhIGF-I for 3 days. GHRH, SRIF and GH mRNA levels were evaluated by Northern and slot blot hybridization. Administration of rhGH (250 micrograms/kg/twice daily, sc) induced a significant inhibition of GHRH and a significant stimulation of SRIF mRNA levels in C rats; GH treatment was, however, ineffective on both neuropeptide mRNA levels in the S group. Continuous infusion of rhIGF-I (300 micrograms/kg/day, sc) induced a significant increase of SRIF levels in both C and S rats but did not modify GHRH mRNA levels in either group. In the pituitary, GH mRNA levels followed a pattern very similar to that of GHRH. These results provide evidence for a direct role of GH in the inhibition of GHRH mRNA levels; IGF-I appears more involved in the direct stimulation of SRIF mRNA levels.


Asunto(s)
Privación de Alimentos/fisiología , Hormona Liberadora de Hormona del Crecimiento/efectos de los fármacos , Hormona de Crecimiento Humana/farmacología , Factor I del Crecimiento Similar a la Insulina/farmacología , ARN Mensajero/efectos de los fármacos , Somatostatina/efectos de los fármacos , Animales , Ingestión de Alimentos , Hormona Liberadora de Hormona del Crecimiento/genética , Hormona Liberadora de Hormona del Crecimiento/metabolismo , Hormona de Crecimiento Humana/administración & dosificación , Hormona de Crecimiento Humana/genética , Humanos , Hipotálamo/química , Hipotálamo/metabolismo , Inyecciones Intraventriculares , Factor I del Crecimiento Similar a la Insulina/administración & dosificación , Factor I del Crecimiento Similar a la Insulina/genética , Masculino , ARN Mensajero/química , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/farmacología , Somatostatina/genética , Somatostatina/metabolismo
4.
J Endocrinol ; 151(2): 195-201, 1996 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-8958779

RESUMEN

To study possible age-related differences in the role of neuronal histaminergic pathways in the control of GH secretion, the effects of alpha-fluoromethylhistidine (alpha-FMH), an irreversible inhibitor of histamine (HA) synthesis, were examined on basal and opioid-induced GH release in neonatal and adult rats. The mechanisms involved in such effects were evaluated by measuring pituitary GH mRNA levels and hypothalamic levels of GH-releasing hormone (GHRH) and somatostatin (SRIF) mRNAs. Daily injection of alpha-FMH (20 mg/kg, s.c.) in pups of either sex, from birth until 10 days of age, caused a significant increase in baseline plasma GH and potentiated the GH response to the [Met5]-enkephalin analog FK 33-824 (1 mg/kg, s.c.) administered 3 h after the last alpha-FMH injection. GH and SRIF mRNA levels were significantly higher in alpha-FMH-treated pups than in controls, whereas no difference was observed in GHRH mRNA levels. In young adult male rats, acute administration of alpha-FMH (100 mg/kg, s.c., 3 h before) did not change significantly basal GH levels but potentiated FK 33-824 (0.3 mg/kg, intracarotid)-induced stimulation of GH secretion. Repeated administration of alpha-FMH (200 micrograms/rat, i.c.v., for 3 days) failed to modify basal and FK 33-824-induced GH secretion, caused a significant reduction in hypothalamic GHRH mRNA levels and left SRIF and GH mRNAs unchanged. These findings indicate that HA exerts an inhibitory effect on GH secretion in both neonatal and adult rats. The different effects of short-term HA depletion on hypothalamic and pituitary indices of somatotropic function observed at the two age periods may be ascribed to the immaturity of the HA system in early postnatal life and to a different functional role of GH-regulatory factors during ontogeny.


Asunto(s)
Envejecimiento/fisiología , Hormona del Crecimiento/metabolismo , Antagonistas de los Receptores Histamínicos/farmacología , Histidina Descarboxilasa/antagonistas & inhibidores , Hipotálamo/metabolismo , Metilhistidinas/farmacología , Análisis de Varianza , Animales , Animales Recién Nacidos , D-Ala(2),MePhe(4),Met(0)-ol-encefalina/farmacología , Femenino , Hormona del Crecimiento/sangre , Hormona Liberadora de Hormona del Crecimiento/genética , Hipotálamo/efectos de los fármacos , Masculino , Hipófisis/química , ARN Mensajero/análisis , Ratas , Ratas Sprague-Dawley , Somatostatina/genética , Aumento de Peso/efectos de los fármacos
6.
Resuscitation ; 9(4): 267-73, 1981 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-7335962

RESUMEN

The clinical course and treatment of 21 critically ill patients suffering from gas gangrene are reported. Analysis of the results has underlined the importance of intensive care and hyperbaric management to prevent the evolution of disease and to improve patients' clinical conditions for surgical procedures.


Asunto(s)
Gangrena Gaseosa/terapia , Oxigenoterapia Hiperbárica , Cefoxitina/uso terapéutico , Gangrena Gaseosa/diagnóstico , Gentamicinas/uso terapéutico , Humanos , Infección de Heridas/microbiología , Infección de Heridas/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA